Evidence map›Paper›PMID 39011480›Full record

ArticleFrontiers in oncology2024

Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck.

Masanobu Sato, Tomohiro Enokida, Takao Fujisawa, Susumu Okano, Naohiro Takeshita, Nobukazu Tanaka, Hideki Tanaka, Atsushi Motegi, Sadamoto Zenda, Takeshi Shinozaki and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Expression and prognostic value of mothers against decapentaplegic homolog 7 in head and neck squamous cell carcinoma].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masanobu SatoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takao FujisawaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Naohiro TakeshitaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Nobukazu TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hideki TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Atsushi MotegiDepartment of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Sadamoto ZendaDepartment of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi ShinozakiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Kazuto MatsuuraDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Ryuichi HayashiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Tetsuo AkimotoDepartment of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The significance of induction chemotherapy (IC) in the treatment of squamous cell carcinoma of the head and neck (SCCHN) with unresectable locoregional recurrence after curative surgery has not been clarified. The aim of this study was to evaluate the efficacy of IC followed by chemoradiotherapy (CRT) in these patients. Methods: Among patients with unresectable locoregional recurrent SCCHN who had not undergone prior irradiation and were eligible for cisplatin, we conducted a retrospective analysis of patients who received CRT following IC with paclitaxel, carboplatin, or cetuximab (IC-PCE group) and those who received CRT without prior IC (CRT group) between June 2013 and August 2021. Result: Forty-two patients were included. The CRT group and IC-PCE group consisted of 15 and 27 patients, respectively. Primary site was the oral cavity (n=25), oropharynx (n=3), hypopharynx (n=13) and larynx (n=1). Objective response rate (ORR) with IC-PCE was 55.6%; 24 patients (88.9%) subsequently received CRT. ORR after completion of CRT was significantly better in the IC-PCE group (95.8% in the IC-PCE group vs. 66.7% in the CRT group, p=0.024). Progression-free survival (PFS) of the total population on median follow-up of 2.4 years (range: 0.8-7.3) tended to be better in the IC-PCE group (2-year PFS: 55.6% in the IC-PCE group vs. 33.3% in the CRT group, log-rank Conclusion: Therapeutic strategies including IC-PCE in patients with unresectable locoregional recurrent SCCHN after curative surgery may contribute to improved prognosis, especially in oral cancer.

Indexed as

cetuximabchemoradiotherapyinduction chemotherapyPCEunresectable squamous cell carcinoma of the head and neck

Identifiers

PMID39011480
PMCPMC11246904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.